United States: Biosimilars, The BPCIA, And Amgen v. Sandoz: The Federal Circuit's First Attempt To Make Sense Of "A Riddle Wrapped In A Mystery Inside An Enigma"

On July 21, 2015, the Federal Circuit issued a key decision regarding the meaning of various provisions of the Biologics Price Competition and Innovation Act (BPCIA). See Amgen Inc. v. Sandoz Inc., Fed. Cir. Case No. 2015-1499. A divided panel of the Court decided two issues on appeal, giving the nod to Sandoz on the first issue and to Amgen on the second. As previously reported in a June 4 post on our Global IP Matters blog, the appeal had been fast-tracked because of the potentially imminent marketing of Sandoz's Zarxio (filgrastim-sndz), which is a biosimilar version of Amgen's Neupogen® (filgrastim). Perhaps for similar reasons, the Court issued its 46-page opinion very quickly – less than two months after the parties' oral argument was held on June 3, 2015.

The Issues

The Federal Circuit's decision focused on two issues, both of which had been decided largely in Sandoz's favor during the district court proceedings:

  1. Whether the BPCIA's patent exchange provisions – specifically, 42 U.S.C. § 262(l)(2)-(6) – are mandatory (Amgen's view) or optional (Sandoz's view), and what the consequences of non-compliance or "opting out" of these exchange provisions should be; and
  2. Whether the 180-day pre-launch notice required under 42 U.S.C. § 262(l)(8) may be given immediately upon FDA's acceptance of the biosimilar application (Sandoz's view) or only upon FDA's approval of the biosimilar product for licensure (Amgen's view).

The Court's Decision

The Court was split 2-1 on both issues, with a different two-judge majority agreeing on each issue. On the first issue, Judges Lourie and Chen sided with Sandoz, affirmed the district court, and held as follows:

[E]ven though under paragraph (l)(2)(A), when read in isolation, a subsection (k) applicant would be required to disclose its aBLA and the manufacturing information to the RPS by the statutory deadline, we ultimately conclude that when a subsection (k) applicant fails the disclosure requirement,42 U.S.C. § 262(l)(9)(C) and 35 U.S.C. § 271(e) expressly provide the only remedies as those being based on a claim of patent infringement. Because Sandoz took a path expressly contemplated by the BPCIA, it did not violate the BPCIA by not disclosing its aBLA and the manufacturing information by the statutory deadline.

Maj. Op. at 15 (emphasis added). Critical to the majority's reasoning was the presence of an express remedy within the BPCIA itself, a remedy that the majority believed was designed to address precisely the path that Sandoz had chosen. Judge Newman dissented from this portion of the opinion, arguing that the BPCIA's disclosure requirements under (l)(2)(A) are mandatory, and that "[t]hese deliberate violations of the requirements of the BPCIA forfeit Sandoz' access to the benefits of the BPCIA." Newman Op. at 2; see also id. at 8 ("Subsection (k) and subsection (l) are components of an integrated framework; to enjoy the benefits of subsection (k), the biosimilar applicant is obligated to comply with subsection (l).").

On the second issue, Judges Lourie and Newman sided with Amgen, reversed the district court, and held as follows:

We ... conclude that, under paragraph (l)(8)(A), a subsection (k) applicant may only give effective notice of commercial marketingafter the FDA has licensed its product. The district court thus erred in holding that a notice of commercial marketing under paragraph (l)(8)(A) may effectively be given before the biological product is licensed....

Maj. Op. at 18 (emphasis added). Judges Lourie and Newman based their decision on the rationale that "[r]equiring that a product be licensed before notice of commercial marketing ensures the existence of a fully crystallized controversy regarding the need for injunctive relief," and that the 180-day post-licensure period therefore "provide[s] a defined statutory window during which the court and the parties can fairly assess the parties' rights prior to the launch of the biosimilar product." Id. at 17. Judges Lourie and Newman also made clear that the (l)(8)(A) notice requirements are mandatory where, as here, a biosimilar applicant "completely fails to provide its aBLA and the required manufacturing information to the RPS by the statutory deadline." Id. at 21.

The majority conceded that, at least in this case, its ruling would effectively provide Amgen with an additional 180 days of market exclusivity for Neupogen. Id. at 18. But the majority argued that this would not necessarily be the case for other reference biologic drugs where the 12-year exclusivity period had not already expired. Id. ("A statute must be interpreted as it is enacted, not especially in light of particular, untypical facts of a given case."). Judge Chen dissented vigorously, arguing that the majority decision results in an "extra-statutory windfall" for Amgen and other reference product sponsors under the BPCIA. Chen Op. at 2. Judge Chen also disagreed that the (l)(8)(A) notice requirements are always mandatory. If a party does not engage in the (l)(2) exchange procedures, Judge Chen reasoned, then (l)(8) "lacks meaning" and "does not apply" (in the same way that (l)(3)-(l)(7) also would not apply). Id. at 6, 10.

What Does the Court's Decision Mean for the Parties?

The practical effects of the Federal Circuit's decision are as follows:

  1. Sandoz may not market its biosimilar filgrastim product until September 2, 2015, which is 180 days from March 6, 2015, the date that Sandoz received FDA licensure/approval for Zarxio. Maj. Op. at 21. Consistent with this finding, the Federal Circuit also extended its injunction pending appeal to September 2, 2015. Id. at 25.
  2. Amgen's state law claims for unfair competition and conversion are dismissed, some on substantive grounds (because Sandoz did not violate the BPCIA with respect to certain of Amgen's claims) and some on mootness grounds (because the 180-day extension through September 2, 2015 provides all the relief Amgen could otherwise obtain on its other claims). Maj. Op. at 22-23.
  3. The case is remanded to the district court for consideration of Amgen's infringement claims and Sandoz's counterclaims regarding U.S. Patent No. 6,162,427 (covering a method of using filgrastim), as well as "any other patents properly brought into the district court action." Maj. Op. at 25. If Amgen wishes to prevent Sandoz from marketing Zarxio after September 2, 2015, it will likely have to obtain an injunction from the district court based on the '427 or other patents (all of which will need to take place in a very short time frame).

What Does the Court's Decision Mean for the BPCIA?

The Federal Circuit's decision in Amgen v. Sandoz is far from the end of the story for the BPCIA. First, there are several important issues — such as that of "preemption" under the BPCIA, or interpretation of other aspects of the Act's patent exchange and dispute resolution provisions — that were not squarely raised by this appeal, and thus were not addressed by the court. See, e.g., Maj. Op. at 21 n.5 (declining to address the preemption issue). Second, given the panel split on both key issues, the case is ripe for en banc rehearing by the full Federal Circuit and potentially for certiorari to the U.S. Supreme Court. Third, without expressly asking Congress to rewrite the BPCIA, the Court did not hesitate to express its frustration with the statute's text. On this point the entire panel of judges even appeared to be in agreement. As Judge Chen wrote, "[t]o fulfill our judicial obligation to say what the law is, we must choose from a series of imperfect choices." Chen Op. at 11 (internal quotations omitted). And as Judges Lourie and Chen wrote in the opening of the Court's opinion:

Winston Churchill once described Russia as "a riddle wrapped in a mystery inside an enigma." Winston Churchill, The Russian Enigma (BBC radio broadcast Oct. 1, 1939), available at http://www.churchill-societylondon.org.uk/RusnEnig.html. That is this statute. In these opinions, we do our best to unravel the riddle, solve the mystery, and comprehend the enigma.

Maj. Op. at 3 n.1.

In other words, and as is usually the case with biosimilars and the BPCIA, stay tuned ...

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:
  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.
  • Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.
    If you do not want us to provide your name and email address you may opt out by clicking here
    If you do not wish to receive any future announcements of products and services offered by Mondaq you may opt out by clicking here

    Terms & Conditions and Privacy Statement

    Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

    Use of www.mondaq.com

    You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


    Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

    The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


    Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

    • To allow you to personalize the Mondaq websites you are visiting.
    • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
    • To produce demographic feedback for our information providers who provide information free for your use.

    Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

    Information Collection and Use

    We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

    We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

    Mondaq News Alerts

    In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


    A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

    Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

    Log Files

    We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


    This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

    Surveys & Contests

    From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


    If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


    From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

    *** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .


    This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

    Correcting/Updating Personal Information

    If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

    Notification of Changes

    If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

    How to contact Mondaq

    You can contact us with comments or queries at enquiries@mondaq.com.

    If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.

    By clicking Register you state you have read and agree to our Terms and Conditions